PT-141
FDA ApprovedAlso known as: Bremelanotide, Vyleesi
Melanocortin & Sexual HealthLast reviewed: April 28, 2026
A synthetic melanocortin receptor agonist derived from Melanotan II. Unlike Melanotan II, PT-141 was developed specifically for sexual dysfunction and received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mechanism of Action
Activates melanocortin receptors (MC3R and MC4R) in the central nervous system, increasing sexual desire through a brain-based mechanism rather than vascular effects. This distinguishes it from PDE5 inhibitors like sildenafil which work peripherally.
Common Uses
- Female sexual dysfunction (FDA-approved indication)
- Male sexual dysfunction (off-label)
- Libido enhancement
- Erectile dysfunction (off-label)
Known Risks
- Nausea (most common side effect — ~40% in trials)
- Flushing
- Headache
- Transient blood pressure increase
- Hyperpigmentation with repeated use
- Injection site reactions
Regulatory Status
FDA-approved as Vyleesi (bremelanotide injection) in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use for male sexual dysfunction is common through telehealth clinics. Available through compounding pharmacies with prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (Vyleesi — FDA-approved)
Typical Dose
1.75 mg
Frequency
As needed, 45 minutes before sexual activity
Cycle Length
No more than once per 24 hours; no more than 1x per day
FDA-approved dose for HSDD in premenopausal women. Off-label use for men is common through telehealth clinics. Nausea is the most common side effect — antiemetics can help. Do not use more than 8 times per month.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.